Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
27.05. | GSK makes new drug submission for depemokimab in Canada | ||
27.05. | What's been agreed at this year's World Health Assembly? | ||
27.05. | Lupin partners SteinCares to commercialise biosimilar in LATAM | ||
27.05. | FDA to review Otsuka's sibeprenlimab application for IgAN | ||
27.05. | Pharmaceutical Technology Excellence Awards 2025: Upperton Pharma Solutions | ||
26.05. | China's CDE grants breakthrough status approval to Abbisko's HCC therapy | ||
26.05. | CHMP recommends GSK's Blenrep approval for multiple myeloma treatment | ||
23.05. | Genentech to onshore US manufacturing amid rising drug pricing tensions | ||
23.05. | ASCO25: Roche's Itovebi combo reduces risk of death in breast cancer by 33% | ||
23.05. | NICE endorses CSL Vifor's sparsentan for IgA nephropathy in adults | ||
23.05. | Obesity therapies and the multi-indication momentum: how industry is responding | ||
23.05. | Medicaid on a spit after Republicans' budget bill passes House by single vote | ||
23.05. | Bayer's Eylea set for longer treatment intervals to challenge Roche's Vabysmo | ||
23.05. | FDA approves GSK's Nucala to treat COPD | ||
23.05. | Aptar Digital to use AstraZeneca's AI algorithms for CKD detection | ||
22.05. | Paratek expands commercial portfolio with Optinose | ||
22.05. | Wegovy and Zepbound costs capped at $200 in new Evernorth programme | ||
22.05. | Lilly's Kisunla marketing for Alzheimer's authorised in Australia | ||
22.05. | UK biopharma innovator venture financing surges to $1.1bn in Q1 2025 | ||
22.05. | Overcoming cold-chain logistical challenges when delivering life-saving MS therapies | ||
22.05. | Orionis and Genentech link on oncology small-molecule glue medicines | ||
21.05. | Moderna shares down after pulling Covid-flu combo vaccine application | ||
21.05. | Can pharma tariffs "Make America Manufacture Again"? | ||
21.05. | Viz.ai, Sanofi and Regeneron to link for COPD management | ||
21.05. | Navigating new EU regulations in the clinical supply chain |